25 General introduction 69. Hentschel AE, Beijert IJ, Bosschieter J, Kauer PC, Vis AN, Lissenberg-Witte BI, et al. Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation. Clinical Epigenetics. 2022;14(1):19. 70. Van Keer S, van Splunter AP, Pattyn J, De Smet A, Herzog SA, Van Ostade X, et al. Triage of human papillomavirus infected women by methylation analysis in first-void urine. Scientific Reports. 2021;11(1):7862. 71. Jordaens S, Zwaenepoel K, Tjalma W, Deben C, Beyers K, Vankerckhoven V, et al. Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods. International Journal of Cancer. 2023;n/a(n/a). 72. Hentschel AE, van den Helder R, van Trommel NE, van Splunter AP, van Boerdonk RAA, van Gent M, et al. The Origin of Tumor DNA in Urine of Urogenital Cancer Patients: Local Shedding and Transrenal Excretion. Cancers (Basel). 2021;13(3). 73. Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, et al. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. J Thorac Oncol. 2016;11(10):1690-700. 74. Wang X, Meng Q, Wang C, Li F, Zhu Z, Liu S, et al. Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression. Biomarkers. 2017;22(7):654-60. 75. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. 76. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016;387(10023):1094-108. 77. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137(5):1621-7. 78. Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, et al. Endometrial cancer: a review and current management strategies: part II. Gynecologic oncology. 2014;134(2):393402. 79. Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018;178(9):1210-22. 80. Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022;399(10333):1412-28. 81. Whelan E, Kalliala I, Semertzidou A, Raglan O, Bowden S, Kechagias K, et al. Risk Factors for Ovarian Cancer: An Umbrella Review of the Literature. Cancers. 2022;14(11):2708. 82. Kyo S, Ishikawa N, Nakamura K, Nakayama K. The fallopian tube as origin of ovarian cancer: Change of diagnostic and preventive strategies. Cancer Medicine. 2020;9(2):421-31. 83. Liberto JM, Chen SY, Shih IM, Wang TH, Wang TL, Pisanic TR, 2nd. Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. Cancers (Basel). 2022;14(12). 84. Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiology, Biomarkers & Prevention. 2019;28(10):1563-79. 1
RkJQdWJsaXNoZXIy MjY0ODMw